NC Medicaid
Pharmacy Prior Approval Request for Leqembi

Leqembi

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext._____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: _____
11. Length of Therapy (in days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days ☐ Other _____

Clinical Information

Initial Authorization:

1. Is the beneficiary age 18 and older? ☐ **Yes** ☐ **No**
2. Does the beneficiary have a diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's dementia? ☐ **Yes** ☐ **No**
3. Does the beneficiary have a Clinical Dementia Rating (CDR)-Global score of 0.5 to 1? ☐ **Yes** ☐ **No**
4. Does the beneficiary have a Memory Box score ≥ 0.5? ☐ **Yes** ☐ **No**
5. Does the beneficiary have a Montreal Cognitive Assessment (MoCA) score 18 to 25 (inclusive) OR equivalent tool indicating MCI or mild dementia (NOTE: range of scores may be adjusted based on educational status of patient)? ☐ **Yes** ☐ **No**
6. Does the beneficiary have an objective evidence of cognitive impairment at screening? ☐ **Yes** ☐ **No**
7. Does the beneficiary have a Positron emission tomography (PET) scan or cerebrospinal fluid (CSF) assessment of amyloid beta (1-42) that is positive for amyloid beta plaque? ☐ **Yes** ☐ **No**
8. Does the prescriber attests other conditions causing similar symptoms have been ruled out (e.g., vascular dementia, dementia with Lewy bodies, frontotemporal dementia, normal pressure hydrocephalus)? ☐ **Yes** ☐ **No**
9. Does the beneficiary have risk factors for intracerebral hemorrhage (e.g., prior cerebral hemorrhage > 1 cm in greatest diameter, more than 4 microhemorrhages, superficial siderosis, evidence of vasogenic edema, evidence of cerebral contusion, aneurysm, vascular malformation, infective lesions, multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel or white matter disease)? ☐ **Yes** ☐ **No**
10. Has the beneficiary had a stroke, transient ischemia attack (TIA), or seizure in the last 12 months? ☐ **Yes** ☐ **No**
11. Has the beneficiary demonstrated clinically significant and unstable psychiatric illness in the last 6 months? ☐ **Yes** ☐ **No**
12. Is the beneficiary currently receiving anti-platelet agents (with the exception of prophylactic aspirin or clopidogrel), anticoagulants (e.g., Factor Xa inhibitors), or anti-thrombins (e.g., heparin)? ☐ **Yes** ☐ **No**
13. Has the beneficiary had a recent (within one year) brain magnetic resonance imaging (MRI) prior to initiating treatment? ☐ **Yes** ☐ **No**
14. Has the baseline disease severity been assessed using an objective measure/tool (e.g., MoCA, Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog-13], Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment version [ADCS-ADL-MCI], Clinical Dementia Rating-Sum of Boxes [CDR-SB])? ☐ **Yes** ☐ **No**
15. Is Leqembi being prescribed by or in consultation with a neurologist or geriatrician or geriatric psychiatrist? ☐ **Yes** ☐ **No**

Re- Authorization: (Please answer 1-15 above and 1- 5 below)

1. Does scoring for the beneficiary on an objective measure/tool (e.g., ADAS-Cog 13; ADCS-ADL-MCI; MMSE; CDR-SB) demonstrates improvement, stability, or slowing of decline in cognitive and/or functional impairment? ☐ **Yes** ☐ **No**
2. Has the beneficiary progresses to moderate or severe Alzheimer's Disease? ☐ **Yes** ☐ **No**
3. Has the beneficiary experienced any treatment-restricting adverse effects (e.g., severe hypersensitivity reactions)? ☐ **Yes** ☐ **No**
4. Has the beneficiary undergone Beneficiary has undergone MRI prior to the 5th, 7th, and 14th infusions to monitor for ARIA with edema (ARIA-E) or ARIA with hemosiderin deposition (ARIA-H)? ☐ **Yes** ☐ **No**

NC Medicaid

Pharmacy Prior Approval Request for Leqembi

5. Will Leqembi administrations be suspended and not resumed until MRI demonstrates radiographic resolution and stabilization of symptoms in the event of any of the following? ☐ **Yes** ☐ **No**

- ARIA-E that is asymptomatic or mildly symptomatic with moderate to severe radiographic severity
- ARIA-E with moderate to severe symptoms and any degree of radiographic severity
- ARIA-H that is asymptomatic with moderate radiographic severity
- ARIA-H with moderate to severe symptoms and any degree of radiographic severity
- ARIA-H with severe radiographic severity

Signature of Prescriber:_____ Date: _____

Fax this form to CSRA at (855) 710-1969 Pharmacy PA Call Center: (866) 246-8505

NC Medicaid

Pharmacy Prior Approval Request for Leqembi

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.